Skip to main content
Sign In

Stuart E. Lind, MD


Education: MD

Cornell University, Ithaca, NY   1972
New York University, New York, NY    1976

Dr. Lind trained in internal medicine at Northwestern University and in hematology-oncology at Massachusetts General Hospital.  He joined the faculty at Harvard Medical School in 1981, and was based at the Massachusetts General Hospital from 1981-1992 and the Brigham and Women’s Hospital from 1992-1994, where he was associate medical director of the blood bank for stem cell processing. In 1994 he moved to the University of Vermont where he served as Director of the Coagulation Laboratory. From 1996-2001 he was on the faculty in hematology-oncology at Northwestern University. From 2001-2006 he was at the University​                  Stuart Lind, MD
 of Oklahoma, serving as Director of the Coagulation Laboratory and associate director of the blood bank, as well as an attending physician in the hematology-oncology section. He moved to UCHSC in March, 2006 and joined the Division of Medical Oncology.  He is board certified in Hematology, Medical Oncology and Blood Banking/Transfusion Medicine.  His clinical interests are in benign and malignant hematology, as well as laboratory medicine.
Dr. Lind’s laboratory research is directed towards: developing metal ionophores as therapeutic agents and coagulation tests to detect hypercoaguability.    

Ding WQ, Liu B, Vaught JL Yamauchi H and Lind SE. Anti-cancer activity of the antibiotic lioquinol. Cancer Res 65:3389-3395, 2005.

Huang X, Ding WQ, Vaught J, Wolf R, Morrissey JH, Harrison RG, Lind SE.  A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.  Blood. 107:980-986,2006.

Ding WQ, Liu B, Vaught JL, Palmiter RD, Lind SE. Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Molecular Cancer Therapeutics.5:1864-1872, 2006.

Wing WQ, Yu H, Lind SE. Zinc-binding compounds induce cancer cell death via distinct modes of action.  Cancer Letters 271:251-259, 2008.

Yu H, Zhou Y, Lind SE, Ding WQ. Clioquinol targets zinc to lysosomes in human cancer cells. Biochem. J. 417:133-139, 2009.  

Lind SE, Park JS, Drexler JW.  Pyrithione and 8-hydroxyquinolines transport lead across erythrocyte membranes. Translational Research 154:153-159, 2009.

Ding WQ, Lind SE. Metal ionophores - an emerging class of anticancer drugs. IUBMB Life 61:1013-1018, 2009.

PubMed Articles